NMPA to deepen cooperation with WHO
Jiao Hong (L), Commissioner of China's National Medical Products Administration (NMPA), meets with Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO). [Photo/nmpa.gov.cn]
Jiao Hong, Commissioner of China's National Medical Products Administration (NMPA), recently signed a statement of intent with Director-General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus.
The two sides agreed to strengthen partnership in drug regulation, especially in the fields of risk assessment, emergency response and global supply of high-quality medicines, in an effort to further improve Chinese people's health and life quality and contribute to the betterment of global public health.
At present, the NMPA and relevant ministries are actively preparing for the forthcoming WHO assessment of China's vaccine national regulatory system in 2021.
Taking this assessment as an opportunity, China's drug regulatory authorities will set up a more scientific and efficient vaccine regulatory system, continuously improve its level and ensure the quality of vaccine products.
Jiao said in the meeting that encouraged by the promulgation of the drug administration law and the vaccine administration law, China's drug regulatory authorities will further deepen reform of the drug review and approval system and improve the regulatory system.
Promotion of extensive and in-depth cooperation with the WHO will be advanced, and China will fulfill its obligations as a responsible big power and propel the development of global public health by providing more high-quality medical products made in China, stressed Jiao.
Dr. Tedros said he believes that China's drug regulatory system has made remarkable achievements and positive contributions to the health of people in China and elsewhere.
The WHO will continue to deepen its partnership with China's drug regulatory authorities and work together for the realization of United Nations' 2030 Goals for Sustainable Development and WHO's vision of universal health coverage.
Officials of the WHO and the NMPA reached consensus in further collaboration in drug regulation. [Photo/nmpa.gov.cn]
The two sides also exchanged views on enhancing cooperation in pharmacovigilance, application for WHO prequalification of China-made drugs and vaccines, Chinese experts' participation in the formulation of relevant international drug standards and technical guidelines, and support for WHO's program of local pharmaceutical production.